Skip to main content
Erschienen in: Clinical Pharmacokinetics 12/2018

04.05.2018 | Review article

Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole

verfasst von: Matthew W. McCarthy, Brad Moriyama, Ruta Petraitiene, Thomas J. Walsh, Vidmantas Petraitis

Erschienen in: Clinical Pharmacokinetics | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

In March 2015, the extended-spectrum triazole antifungal isavuconazole was granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. Isavuconaozle has activity against a broad range of yeasts, dimorphic fungi, and molds and is associated with fewer toxicities than voriconazole. It also has predictable pharmacokinetics in adults, fewer drug–drug interactions than many existing antifungal agents, and is available in both oral and β-cyclodextrin-free intravenous formulations. In this review, we explore what is known about the pharmacokinetics and pharmacodynamics of isavuconazole and look ahead to its expanding applications in clinical practice.
Literatur
1.
Zurück zum Zitat Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother. 2006;57(1):135–8.CrossRef Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother. 2006;57(1):135–8.CrossRef
5.
Zurück zum Zitat Lepak AJ, Marchillo K, Vanhecker J, Andes DR. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57(12):6284–9.CrossRef Lepak AJ, Marchillo K, Vanhecker J, Andes DR. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 2013;57(12):6284–9.CrossRef
6.
Zurück zum Zitat Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):286–93.CrossRef Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):286–93.CrossRef
7.
Zurück zum Zitat Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52(4):1396–400.CrossRef Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52(4):1396–400.CrossRef
8.
Zurück zum Zitat Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015;35(11):1037–51.CrossRef Rybak JM, Marx KR, Nishimoto AT, Rogers PD. Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015;35(11):1037–51.CrossRef
9.
Zurück zum Zitat Pettit NN, Carver PL. Isavuconazole: a new option for the management of invasive fungal infections. Ann Pharmacother. 2015;49(7):825–42.CrossRef Pettit NN, Carver PL. Isavuconazole: a new option for the management of invasive fungal infections. Ann Pharmacother. 2015;49(7):825–42.CrossRef
10.
Zurück zum Zitat Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol. 2012;8(6):759–65.CrossRef Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol. 2012;8(6):759–65.CrossRef
11.
Zurück zum Zitat Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54(8):572–80.CrossRef Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54(8):572–80.CrossRef
12.
Zurück zum Zitat Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9.CrossRef Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9.CrossRef
13.
Zurück zum Zitat Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–37.CrossRef Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–37.CrossRef
14.
Zurück zum Zitat Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs. 2016;76(17):1647–57.CrossRef Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs. 2016;76(17):1647–57.CrossRef
15.
Zurück zum Zitat Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):279–85.CrossRef Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):279–85.CrossRef
16.
Zurück zum Zitat Ledoux MP, Denis J, Nivoix Y, Herbrecht R. Isavuconazole a new broad-spectrum azole Part 2 pharmacokinetics and clinical activity. J Mycol Med. 2018;28(1):15–22.CrossRef Ledoux MP, Denis J, Nivoix Y, Herbrecht R. Isavuconazole a new broad-spectrum azole Part 2 pharmacokinetics and clinical activity. J Mycol Med. 2018;28(1):15–22.CrossRef
17.
Zurück zum Zitat Ahmed Y, Delaney S, Markarian A. Successful Isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome. Am J Otolaryngol. 2016;37(2):152–5.CrossRef Ahmed Y, Delaney S, Markarian A. Successful Isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome. Am J Otolaryngol. 2016;37(2):152–5.CrossRef
18.
Zurück zum Zitat Türel O. Newer antifungal agents. Expert Rev Anti Infect Ther. 2011;9(3):325–38.CrossRef Türel O. Newer antifungal agents. Expert Rev Anti Infect Ther. 2011;9(3):325–38.CrossRef
19.
Zurück zum Zitat Roilides E, Antachopoulos C. Isavuconazole: an azole active against mucormycosis. Lancet Infect Dis. 2016;16(7):761–2.CrossRef Roilides E, Antachopoulos C. Isavuconazole: an azole active against mucormycosis. Lancet Infect Dis. 2016;16(7):761–2.CrossRef
20.
Zurück zum Zitat Kabulski GM, MacVane SH. Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation. Transpl Infect Dis. 2018;55:e12878.CrossRef Kabulski GM, MacVane SH. Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation. Transpl Infect Dis. 2018;55:e12878.CrossRef
21.
Zurück zum Zitat Steinmann J, Dittmer S, Houbraken J, Buer J, Rath PM. In vitro activity of isavuconazole against Rasamsonia species. Antimicrob Agents Chemother. 2016;60(11):6890–1.CrossRef Steinmann J, Dittmer S, Houbraken J, Buer J, Rath PM. In vitro activity of isavuconazole against Rasamsonia species. Antimicrob Agents Chemother. 2016;60(11):6890–1.CrossRef
22.
Zurück zum Zitat Kovanda LL, Desai AV, Lu Q, Townsend RW, Akhtar S, Bonate P, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL Study). Antimicrob Agents Chemother. 2016;60(8):4568–76.CrossRef Kovanda LL, Desai AV, Lu Q, Townsend RW, Akhtar S, Bonate P, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL Study). Antimicrob Agents Chemother. 2016;60(8):4568–76.CrossRef
23.
Zurück zum Zitat Badali H, Mohammadi R, Mashedi O, de Hoog GS, Meis JF. In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses. 2015;58(5):303–7.CrossRef Badali H, Mohammadi R, Mashedi O, de Hoog GS, Meis JF. In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs. Mycoses. 2015;58(5):303–7.CrossRef
24.
Zurück zum Zitat Thompson GR, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother. 2009;64(1):79–83.CrossRef Thompson GR, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother. 2009;64(1):79–83.CrossRef
25.
Zurück zum Zitat Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016;12:1197–206.CrossRef Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016;12:1197–206.CrossRef
26.
Zurück zum Zitat Townsend R, Kato K, Hale C, Kowalski D, Lademacher C, Yamazaki T, et al. Two phase 1, open-label, mass balance studies to determine the pharmacokinetics of 14 C-labeled isavuconazonium sulfate in healthy male volunteers. Clin Pharmacol Drug Dev. 2018;7(2):207–16.CrossRef Townsend R, Kato K, Hale C, Kowalski D, Lademacher C, Yamazaki T, et al. Two phase 1, open-label, mass balance studies to determine the pharmacokinetics of 14 C-labeled isavuconazonium sulfate in healthy male volunteers. Clin Pharmacol Drug Dev. 2018;7(2):207–16.CrossRef
27.
Zurück zum Zitat Petraitis V, Petraitiene R, Moradi PW, Strauss GE, Katragkou A, Kovanda LL, et al. Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2016;60(5):2718–26.CrossRef Petraitis V, Petraitiene R, Moradi PW, Strauss GE, Katragkou A, Kovanda LL, et al. Pharmacokinetics and concentration-dependent efficacy of isavuconazole for treatment of experimental invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2016;60(5):2718–26.CrossRef
28.
Zurück zum Zitat Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol. 2013;51(8):2608–16.CrossRef Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol. 2013;51(8):2608–16.CrossRef
29.
Zurück zum Zitat Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Guinea J, Hagen F, Meis JF, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother. 2015;59(1):666–8.CrossRef Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Guinea J, Hagen F, Meis JF, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother. 2015;59(1):666–8.CrossRef
30.
Zurück zum Zitat Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother. 2007;51(5):1818–21.CrossRef Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother. 2007;51(5):1818–21.CrossRef
31.
Zurück zum Zitat Wiederhold NP, Kovanda L, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, et al. Isavuconazole is effective for the treatment of experimental cryptococcal meningitis. Antimicrob Agents Chemother. 2016;60(9):5600–3.CrossRef Wiederhold NP, Kovanda L, Najvar LK, Bocanegra R, Olivo M, Kirkpatrick WR, et al. Isavuconazole is effective for the treatment of experimental cryptococcal meningitis. Antimicrob Agents Chemother. 2016;60(9):5600–3.CrossRef
32.
Zurück zum Zitat Desai A, Schmitt-Hoffmann AH, Mujais S, Townsend R. Population Pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment. Antimicrob Agents Chemother. 2016;60(5):3025–31.CrossRef Desai A, Schmitt-Hoffmann AH, Mujais S, Townsend R. Population Pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment. Antimicrob Agents Chemother. 2016;60(5):3025–31.CrossRef
33.
Zurück zum Zitat Schmitt-Hoffmann A, Roos B, Spickermann J, Heep M, Peterfaí E, Edwards DJ, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009;53(11):4885–90.CrossRef Schmitt-Hoffmann A, Roos B, Spickermann J, Heep M, Peterfaí E, Edwards DJ, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother. 2009;53(11):4885–90.CrossRef
34.
Zurück zum Zitat Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61(10):1558–65.CrossRef Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61(10):1558–65.CrossRef
35.
Zurück zum Zitat Donnelley MA, Zhu ES, Thompson GR. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016;9:79–86.PubMedPubMedCentral Donnelley MA, Zhu ES, Thompson GR. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016;9:79–86.PubMedPubMedCentral
36.
Zurück zum Zitat Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population Pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60(9):5483–91.CrossRef Desai A, Kovanda L, Kowalski D, Lu Q, Townsend R, Bonate PL. Population Pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi. Antimicrob Agents Chemother. 2016;60(9):5483–91.CrossRef
37.
Zurück zum Zitat Kovanda LL, Petraitiene R, Petraitis V, Walsh TJ, Desai A, Bonate P, et al. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. J Antimicrob Chemother. 2016;71(7):1885–91.CrossRef Kovanda LL, Petraitiene R, Petraitis V, Walsh TJ, Desai A, Bonate P, et al. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. J Antimicrob Chemother. 2016;71(7):1885–91.CrossRef
38.
Zurück zum Zitat Collins PW. Personalized prophylaxis. Haemophilia. 2012;18(Suppl. 4):131–5.CrossRef Collins PW. Personalized prophylaxis. Haemophilia. 2012;18(Suppl. 4):131–5.CrossRef
39.
Zurück zum Zitat McCarthy MW, Denning DW, Walsh TJ. Future research priorities in fungal resistance. J Infect Dis. 2017;216(Suppl. 3):S484–92.CrossRef McCarthy MW, Denning DW, Walsh TJ. Future research priorities in fungal resistance. J Infect Dis. 2017;216(Suppl. 3):S484–92.CrossRef
40.
Zurück zum Zitat Cornely OA, Böhme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078–85.CrossRef Cornely OA, Böhme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078–85.CrossRef
41.
Zurück zum Zitat Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother. 2009;53(8):3453–61.CrossRef Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother. 2009;53(8):3453–61.CrossRef
42.
Zurück zum Zitat Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother. 2013;57(11):5642–8.CrossRef Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother. 2013;57(11):5642–8.CrossRef
44.
Zurück zum Zitat Seyedmousavi S, Brüggemann RJ, Meis JF, Melchers WJ, Verweij PE, Mouton JW. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother. 2015;59(5):2855–66.CrossRef Seyedmousavi S, Brüggemann RJ, Meis JF, Melchers WJ, Verweij PE, Mouton JW. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother. 2015;59(5):2855–66.CrossRef
45.
Zurück zum Zitat Box H, Livermore J, Johnson A, McEntee L, Felton TW, Whalley S, et al. Pharmacodynamics of isavuconazole in a dynamic in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2015;60(1):278–87.CrossRef Box H, Livermore J, Johnson A, McEntee L, Felton TW, Whalley S, et al. Pharmacodynamics of isavuconazole in a dynamic in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2015;60(1):278–87.CrossRef
46.
Zurück zum Zitat Desai A, Yamazaki T, Dietz AJ, Kowalski D, Lademacher C, Pearlman H, et al. Pharmacokinetic and pharmacodynamic evaluation of the drug-drug interaction between isavuconazole and warfarin in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):86–92.CrossRef Desai A, Yamazaki T, Dietz AJ, Kowalski D, Lademacher C, Pearlman H, et al. Pharmacokinetic and pharmacodynamic evaluation of the drug-drug interaction between isavuconazole and warfarin in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):86–92.CrossRef
47.
Zurück zum Zitat Yamazaki T, Desai A, Goldwater R, Han D, Lasseter KC, Howieson C, et al. Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):66–75.CrossRef Yamazaki T, Desai A, Goldwater R, Han D, Lasseter KC, Howieson C, et al. Pharmacokinetic interactions between isavuconazole and the drug transporter substrates atorvastatin, digoxin, metformin, and methotrexate in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):66–75.CrossRef
48.
Zurück zum Zitat Groll AH, Desai A, Han D, Howieson C, Kato K, Akhtar S, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76–85.CrossRef Groll AH, Desai A, Han D, Howieson C, Kato K, Akhtar S, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76–85.CrossRef
49.
Zurück zum Zitat Ledoux MP, Toussaint E, Denis J, Herbrecht R. New pharmacological opportunities for the treatment of invasive mould diseases. J Antimicrob Chemother. 2017;72(1):i48–58.CrossRef Ledoux MP, Toussaint E, Denis J, Herbrecht R. New pharmacological opportunities for the treatment of invasive mould diseases. J Antimicrob Chemother. 2017;72(1):i48–58.CrossRef
50.
Zurück zum Zitat Townsend R, Dietz A, Hale C, Akhtar S, Kowalski D, Lademacher C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):44–53.CrossRef Townsend R, Dietz A, Hale C, Akhtar S, Kowalski D, Lademacher C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):44–53.CrossRef
51.
Zurück zum Zitat Yamazaki T, Desai A, Goldwater R, Han D, Howieson C, Akhtar S, et al. Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):54–65.CrossRef Yamazaki T, Desai A, Goldwater R, Han D, Howieson C, Akhtar S, et al. Pharmacokinetic effects of isavuconazole coadministration with the cytochrome P450 enzyme substrates bupropion, repaglinide, caffeine, dextromethorphan, and methadone in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):54–65.CrossRef
52.
Zurück zum Zitat Yamazaki T, Desai A, Han D, Kato K, Kowalski D, Akhtar S, et al. Pharmacokinetic interaction between isavuconazole and a fixed-dose combination of lopinavir 400 mg/ritonavir 100 mg in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):93–101.CrossRef Yamazaki T, Desai A, Han D, Kato K, Kowalski D, Akhtar S, et al. Pharmacokinetic interaction between isavuconazole and a fixed-dose combination of lopinavir 400 mg/ritonavir 100 mg in healthy subjects. Clin Pharmacol Drug Dev. 2017;6(1):93–101.CrossRef
53.
Zurück zum Zitat Gebremariam T, Wiederhold NP, Alqarihi A, Uppuluri P, Azie N, Edwards JE, et al. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. J Antimicrob Chemother. 2017;72(2):462–6.CrossRef Gebremariam T, Wiederhold NP, Alqarihi A, Uppuluri P, Azie N, Edwards JE, et al. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis. J Antimicrob Chemother. 2017;72(2):462–6.CrossRef
54.
Zurück zum Zitat Ordaya EE, Alangaden GJ. Real-life use of isavuconazole in patients intolerant to other azoles. Clin Infect Dis. 2016;63(11):1529–30.CrossRef Ordaya EE, Alangaden GJ. Real-life use of isavuconazole in patients intolerant to other azoles. Clin Infect Dis. 2016;63(11):1529–30.CrossRef
55.
Zurück zum Zitat Perkhofer S, Lechner V. Lass-Flörl C; European Committee on Antimicrobial Susceptibility Testing. In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2009;53(4):1645–7.CrossRef Perkhofer S, Lechner V. Lass-Flörl C; European Committee on Antimicrobial Susceptibility Testing. In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2009;53(4):1645–7.CrossRef
56.
Zurück zum Zitat González GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol. 2009;47(1):71–6.CrossRef González GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol. 2009;47(1):71–6.CrossRef
Metadaten
Titel
Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole
verfasst von
Matthew W. McCarthy
Brad Moriyama
Ruta Petraitiene
Thomas J. Walsh
Vidmantas Petraitis
Publikationsdatum
04.05.2018
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 12/2018
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-0673-2

Weitere Artikel der Ausgabe 12/2018

Clinical Pharmacokinetics 12/2018 Zur Ausgabe

Acknowledgement to Referees

Acknowledgement to Referees